From Chemotherapy to Targeted Pills: A New Era in Chronic Myeloid Leukemia and What Asciminib Could Mean for Patients ...

Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Hot Research to Be Presented at ASH 2008 Results from several phase 3 trials will be presented at the upcoming meeting of the American Society of Hematology. Medscape Medical News, December 02, 2008 ...

Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies; ROCKVIL ...

Researchers are exploring new treatment options for chronic myeloid leukemia (CML). Many treatments that have recently been studied or are currently under investigation are targeted therapy drugs. CML ...

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, integrated biopharmaceutical company engaged in the ...